GeoVax Labs, Inc. (GOVX) shareholders
Close on Nov 17, 2026Market cap $14.81MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Waqas Khatri Joint filing with Ayrton Capital LLC (9.99%), Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (9.99%) | 4,810,451 | 9.99% | 13G (passive) | Dec 31, 2025 |
| Mitchell P. Kopin Joint filing with Daniel B. Asher (9.99%), Intracoastal Capital LLC (9.99%) | 2,849,344 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Armistice Capital, LLC Joint filing with Steven Boyd (9.99%) | 291,155 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Intracoastal Capital LLC Joint filing with Mitchell P. Kopin (9.99%), Daniel B. Asher (9.99%) | 233,337 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GOVX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jane Street Group, LLC | 315,275 | 4.28% | $400.40K | New | 0.00% |
| Hrt Financial LP | 126,704 | 1.72% | $160.00K | New | 0.00% |
| Geode Capital Management, LLC | 21,112 | 0.29% | $26.81K | −14,964 | 0.00% |
| Two Sigma Securities, LLC | 10,682 | 0.14% | $13.57K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 5,068 | 0.07% | $6.44K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 3,502 | 0.05% | $4.45K | −25 | 0.00% |
| Vanguard Capital Management LLC | 3,217 | 0.04% | $4.09K | – | 0.00% |
| SBI Securities Co., Ltd. | 2,588 | 0.04% | $3.29K | +2,204 | 0.00% |
| Morgan Stanley | 2,003 | 0.03% | $2.54K | +1,997 | 0.00% |
| Jones Financial Companies Lllp | 1,000 | 0.01% | $1.32K | New | 0.00% |
| UBS Group AG | 944 | 0.01% | $1.20K | −3,304 | 0.00% |
| BlackRock, Inc. | 842 | 0.01% | $1.07K | −251 | 0.00% |
| Citigroup Inc | 230 | 0.00% | $292 | New | 0.00% |
| Wells Fargo & Company/Mn | 30 | 0.00% | $38 | −1 | 0.00% |
| Danske Bank A/S | 3 | 0.00% | $4 | – | 0.00% |
| FMR LLC | 1 | 0.00% | $1 | – | 0.00% |
| Royal Bank of Canada | 1 | 0.00% | $0 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 17 | 0M | 6.7% | 5 / 2 | 5 / 4 | 0M | 0M |
| Q1 2026 | 16 | 0M | 4.5% | 15 / 1 | 0 / 0 | 0M | 0M |
| Q4 2025 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
4 funds held GOVX in Q2 2026, 12% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of GOVX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 22,245 | 0.30% | $45.82K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 3,217 | 0.04% | $4.09K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 856 | 0.01% | $1.76K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 576 | 0.01% | $1.19K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David A. Dodd | President, CEO, Director | 36,661 | 0.50% | Jun 22, 2026 |
| John W. Sharkey | VP, Business Development | 6,191 | 0.08% | Jun 22, 2026 |
| Kelly T. McKee Jr. | Chief Medical Officer | 3,494 | 0.05% | Jun 22, 2026 |
| Mark J. Newman | Chief Scientific Officer | 3,000 | 0.04% | Jun 22, 2026 |
| Mark Reynolds | CFO | 14,013 | 0.19% | Jun 22, 2026 |
| Manpreet Uppal | Director | – | – | Nov 3, 2026 |
| Steven Collier Brown | Director | – | – | Nov 3, 2026 |
| Randal D. Chase | Director | 36,613 | 0.50% | Jun 22, 2026 |
| Dean G. Kollintzas | Director | 11,987 | 0.16% | Jun 22, 2026 |
| John N. Spencer Jr | Director | 21,402 | 0.29% | Jun 22, 2026 |
| Nicole Lemerond | Director | – | – | Jun 22, 2026 |
| Jayne Morgan | Director | – | – | Jun 22, 2026 |
| Robert T. McNally | Director | 66,280 | 0.90% | Jun 22, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John N. Spencer Jr Director | Oct 17, 2025 | Buy | +10,000 | $0.55 | $5.50K | 21,402 |
| Kelly T. McKee Jr. Chief Medical Officer | Aug 7, 2025 | Buy | +1,107 | $0.67 | $742 | 3,494 |
| John N. Spencer Jr Director | Apr 10, 2025 | Buy | +10,000 | $0.98 | $9.80K | 11,402 |
| John W. Sharkey VP, Business Development | Apr 10, 2025 | Buy | +6,000 | $0.99 | $5.94K | 6,191 |
| David A. Dodd President, CEO, Director | Apr 1, 2025 | Buy | +10,000 | $1.08 | $10.80K | 36,661 |
| Mark Reynolds CFO | Mar 31, 2025 | Buy | +6,800 | $1.08 | $7.34K | 14,013 |
| David A. Dodd President, CEO, Director | Aug 9, 2024 | Buy | +8,000 | $1.95 | $15.60K | 26,661 |
| David A. Dodd President, CEO, Director | Feb 22, 2024 | Buy | +8,209 | $2.27 | $18.63K | 18,661 |
| David A. Dodd President, CEO, Director | Feb 21, 2024 | Buy | +520 | $2.15 | $1.12K | 10,452 |
| Mark Reynolds CFO | Feb 7, 2024 | Buy | +2,000 | $2.77 | $5.54K | 7,213 |
| Kelly T. McKee Jr. Chief Medical Officer | Dec 22, 2023 | Buy | +6,944 | $0.36 | $2.50K | 35,782 |
| Kelly T. McKee Jr. Chief Medical Officer | Sep 25, 2023 | Buy | +9,653 | $0.52 | $5.02K | 28,838 |
| David A. Dodd President, CEO, Director | Aug 25, 2023 | Buy | +35,087 | $0.57 | $20.00K | 148,957 |
| Mark Reynolds CFO | Aug 18, 2023 | Buy | +10,000 | $0.52 | $5.20K | 78,184 |
| David A. Dodd President, CEO, Director | Apr 24, 2023 | Buy | +32,000 | $0.64 | $20.48K | 113,870 |
| Mark Reynolds CFO | Apr 20, 2023 | Buy | +8,000 | $0.63 | $5.04K | 68,184 |
| Randal D. Chase Director | Sep 21, 2022 | Buy | +10,000 | $1.10 | $11.00K | 36,613 |
| John W. Sharkey VP, Business Development | Jul 1, 2022 | Buy | +1,000 | $0.82 | $820 | 2,860 |
| Kelly T. McKee Jr. Chief Medical Officer | Jun 27, 2022 | Buy | +4,464 | $1.12 | $5.00K | 19,185 |
| Randal D. Chase Director | Jun 21, 2022 | Buy | +10,000 | $1.21 | $12.10K | 26,613 |
| Kelly T. McKee Jr. Chief Medical Officer | May 5, 2022 | Buy | +9,722 | $0.72 | $7.00K | 14,721 |
| Kelly T. McKee Jr. Chief Medical Officer | May 4, 2022 | Buy | +4,999 | $0.71 | $3.55K | 4,999 |
| Randal D. Chase Director | Sep 29, 2020 | Buy | +16,613 | $5.00 | $83.07K | 16,613 |
| Mark Reynolds CFO | Sep 29, 2020 | Buy | +60,184 | $5.00 | $300.92K | 60,184 |
| David A. Dodd President, CEO, Director | Sep 29, 2020 | Buy | +81,870 | $5.00 | $409.35K | 81,870 |
| Dean G. Kollintzas Director | Sep 29, 2020 | Buy | +11,987 | $5.00 | $59.94K | 11,987 |
| Robert T. McNally Director | Sep 29, 2020 | Buy | +53,925 | $5.00 | $269.63K | 53,925 |
| John N. Spencer Jr Director | Sep 29, 2020 | Buy | +21,024 | $5.00 | $105.12K | 21,024 |
| Randal D. Chase Director | May 5, 2015 | Buy | +200 | $0.19 | $38 | 40,000 |
| Randal D. Chase Director | May 5, 2015 | Buy | +9,800 | $0.19 | $1.86K | 39,800 |
| Mark Reynolds CFO | Apr 23, 2015 | Buy | +10,000 | $0.18 | $1.80K | 66,000 |
| Mark Reynolds CFO | Apr 22, 2015 | Buy | +10,000 | $0.17 | $1.70K | 46,000 |
| Mark Reynolds CFO | Apr 22, 2015 | Buy | +10,000 | $0.17 | $1.70K | 56,000 |
| John N. Spencer Jr Director | Apr 20, 2015 | Buy | +18,000 | $0.17 | $3.06K | 46,625 |
| Randal D. Chase Director | Apr 20, 2015 | Buy | +30,000 | $0.17 | $5.10K | 30,000 |
| Harriet L. Robinson Chief Scientific Officer, Director | Jun 5, 2013 | Gift | −27,500 | – | – | 1,173,726 |
| Mark Reynolds CFO | Jan 31, 2012 | Buy | +15,000 | $0.67 | $10.05K | 36,000 |
| Steven S. Antebi Director | Jan 16, 2012 | Buy | +30,000 | $0.67 | $20.10K | 30,000 |
| John N. Spencer Jr Director | Dec 30, 2011 | Buy | +14,925 | $0.67 | $10.00K | 28,625 |
| Dean G. Kollintzas Director | Dec 30, 2011 | Buy | +14,925 | $0.67 | $10.00K | 14,925 |
| David A. Dodd Director | Dec 30, 2011 | Buy | +112,000 | $0.67 | $75.04K | 127,725 |
| Robert T. McNally President/CEO, Director | Dec 30, 2011 | Buy | +29,850 | $0.67 | $20.00K | 29,850 |
| Mark Reynolds CFO | Dec 30, 2011 | Buy | +15,000 | $0.67 | $10.05K | 21,000 |
| Harriet L. Robinson Chief Scientific Officer, Director | Dec 30, 2011 | Buy | +149,254 | $0.67 | $100.00K | 1,201,226 |
| Harriet L. Robinson Chief Scientific Officer, Director | Jun 22, 2011 | Gift | −7,422 | – | – | 1,051,972 |
| Harriet L. Robinson Chief Scientific Officer, Director | Jan 6, 2011 | Gift | −9,714 | – | – | 1,059,394 |
| Harriet L. Robinson Chief Scientific Officer, Director | Dec 20, 2010 | Gift | −33,333 | – | – | 1,069,108 |
| Robert T. McNally President & CEO, Director | Oct 15, 2010 | Gift | −8,300 | – | – | 0 |
| Mark Reynolds Chief Financial Officer | Jul 2, 2010 | Buy | +1,000 | $2.50 | $2.50K | 6,000 |
| Mark J. Newman VP, Research & Development | Jun 11, 2010 | Buy | +2,000 | $3.32 | $6.64K | 3,000 |
| Mark J. Newman VP, Research & Development | Jun 11, 2010 | Buy | +1,000 | $3.25 | $3.25K | 1,000 |
| Harriet L. Robinson Chief Scientific Officer, Director | Jun 10, 2010 | Buy | +2,100 | $3.35 | $7.04K | 1,102,441 |
| Harriet L. Robinson Chief Scientific Officer, Director | Jun 10, 2010 | Buy | +3,000 | $3.30 | $9.90K | 1,100,341 |
| Robert T. McNally President & CEO, Director | Jun 10, 2010 | Buy | +300 | $3.30 | $990 | 8,300 |
| Donald G. Hildebrand Director | Jun 9, 2010 | Buy | +1,000 | $3.29 | $3.29K | 19,000 |
| Robert T. McNally President & CEO, Director | Jun 9, 2010 | Buy | +100 | $3.30 | $330 | 7,100 |
| Robert T. McNally President & CEO, Director | Jun 9, 2010 | Buy | +900 | $3.32 | $2.99K | 8,000 |
| Mark Reynolds Chief Financial Officer | Jun 9, 2010 | Buy | +530 | $3.35 | $1.78K | 5,000 |
| Mark Reynolds Chief Financial Officer | Jun 9, 2010 | Buy | +570 | $3.34 | $1.90K | 4,470 |
| Mark Reynolds Chief Financial Officer | Jun 9, 2010 | Buy | +1,004 | $3.29 | $3.30K | 3,900 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of GeoVax Labs's stock actually held short. Settlement fails (shares not delivered on time) peaked at 372,671 shares on Oct 6, 2026 over the last 90 days.
See a number that looks wrong?